^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)

    i
    Other names: GRIK2, Glutamate Ionotropic Receptor Kainate Type Subunit 2, GluK2, GLUR6, MRT6, Glutamate Receptor Ionotropic, Kainate 2, Excitatory Amino Acid Receptor 4, Glutamate Receptor 6, GluR-6, EAA4, Glutamate Receptor, Ionotropic, Kainate 2, Putative NMDtranscript(Cassette_171nt), Glutamate Receptor Form A, Glutamate Receptor Form B, Glutamate Receptor Form C, Glutamate Receptor Form D, Glutamate Receptor Form E, GluK2(Alt_5'UTR), BA487F5.1, NEDLAS, GLUK6, GluR6, GLR6
    Associations

    News

    Trials
    3ms
    A prognostic gene signature derived from aging-related genes predicts survival, immune landscape and therapy response in glioma. (PubMed, Mol Clin Oncol)
    RT-qPCR results further confirmed differential expression patterns of the 8 genes between normal and GBM cells, supporting their involvement in GBM pathogenesis. This 8-gene risk model effectively predicts glioma prognosis and supports personalized treatment strategies by highlighting immune microenvironment differences and drug sensitivities between risk groups.
    Journal • Gene Signature
    |
    GADD45G (Growth Arrest And DNA Damage Inducible Gamma) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2) • RBP1 (Retinol Binding Protein 1)
    10ms
    Single-nucleus RNA sequencing of rostral ventromedial medulla in mice with trigeminal neuralgia. (PubMed, Int J Neurosci)
    We inferred cell-state-specific communication in various cell types. Our findings provide potential targets such as Slit2-Robo 1/2, Gabrg3, Gabra2, Grm4, Grik2, Cadps2 and Camk4 on therapeutic strategies for neuropathic or orofacial pain.
    Preclinical • Journal
    |
    SLIT2 (Slit Guidance Ligand 2) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    10ms
    Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma. (PubMed, Commun Biol)
    The landscape of cytokines, checkpoint ligands and receptors uncovered Mrc1, PD-L1, TIM-3 or B7-H3, among the immunotherapy targets that can be addressed in this model. The comparison with human GBMs unveiled crucial similarities with TMEMed GBM, the most frequent subtype.
    Preclinical • Journal
    |
    PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule) • CD73 (5'-Nucleotidase Ecto) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IRF8 (Interferon Regulatory Factor 8) • NT5E (5'-Nucleotidase Ecto) • CSF1R (Colony stimulating factor 1 receptor) • TGFB1 (Transforming Growth Factor Beta 1) • MRC1 (Mannose Receptor C-Type 1) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2) • KCNN4 (Potassium Calcium-Activated Channel Subfamily N Member 4)
    1year
    Anti-GluK2 antibody-positive autoimmune encephalitis concurrent with multiple myeloma: a case report. (PubMed, BMC Neurol)
    This case suggests that involuntary movements and psychiatric symptoms may represent novel phenotypes of anti-GluK2 antibody-associated autoimmune encephalitis. The findings underscore the importance of recognizing the diverse clinical presentations of this rare condition and prompt further research into its underlying mechanisms.
    Journal
    |
    GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    |
    bortezomib • cyclophosphamide
    1year
    Frequency, characteristics, and immunological accompaniments of ataxia in anti-NMDAR antibody-associated encephalitis. (PubMed, Front Immunol)
    Cerebellar ataxia in NMDAR-E may not be explained by concomitant KLHL11, MOG, AQP-4, or GluK2 autoimmunity. Of note, ataxia in NMDAR-E may result from treatment complications and, most interestingly, from MS manifesting in temporal association with NMDAR-E.
    Observational data • Journal
    |
    GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    1year
    Anti-GluK2 Encephalitis in an Asian Child: A Case Report and Literature Review. (PubMed, Immunotargets Ther)
    The intravenous methylprednisolone, immunoglobulin, antibiotics and other symptomatic treatments helped the patient to recover full...Our report provides more evidence that anti-GluK2 antibodies may be pathogenic for the autoimmune encephalitis (cerebellitis). Immunotherapy can be used to treat it with good outcome.
    Review • Journal
    |
    IL6 (Interleukin 6) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    |
    IL6 elevation
    |
    methylprednisolone sodium succinate
    over1year
    A novel signature of seven aging-related genes for risk stratification, prognosis prediction and benefit evaluation of chemotherapy, and immunotherapy in elderly patients with lung adenocarcinoma. (PubMed, Heliyon)
    And novel immunotherapy and chemotherapy regimens were accordingly proposed for the elderly LUAD patients. We identified a novel gene signature based on seven ARGs for risk stratification, prognosis prediction and benefit evaluation of immunotherapy and chemotherapy in elderly LUAD patients.
    Journal • IO biomarker
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • CD79A (CD79a Molecule) • CDX2 (Caudal Type Homeobox 2) • COL1A1 (Collagen Type I Alpha 1 Chain) • CDK3 (Cyclin Dependent Kinase 3) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    almost2years
    Neuronal antibodies in nonparaneoplastic autoimmune cerebellar ataxias. (PubMed, Curr Opin Neurol)
    The number of antibodies against surface antigens is increasing in ACA, but the response to the immunotherapy remains suboptimal. More studies are needed to clarify the role of most of the antibodies against intracellular antigens described in these patients.
    Journal
    |
    GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2) • SEPTIN5 (Septin 5)
    2years
    Epigenetic signature discriminates lymphatic metastasis in BRAF wild-type thyroid carcinoma: methylation role of GRIK2. (PubMed, Epigenomics)
    GRIK2, downregulated due to promoter hypermethylation, acted as a TC suppressor. Our 5-CpG epigenetic signature effectively discriminates lymphatic metastasis in BRAF wild-type TC, highlighting GRIK2's tumor-suppressive role influenced by promoter hypermethylation.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TAGLN (Transgelin) • GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)
    |
    BRAF wild-type
    2years
    Preclinical Efficacy and Safety Assessment of AMT-260, a Novel AAV9-Dual MicroRNA-Based Vector Targeting GRIK2 for the Treatment of Temporal Lobe Epilepsy (AES 2023)
    We administered the AAV9-vector carrying two small interfering RNAs targeting GRIK2 (AMT-260) bilaterally into the hippocampus of a mouse model for TLE (pilocarpine) and into non-human primates (NHP). With the preclinical efficacy in pharmacology models and a good safety profile, AMT-260 will proceed into clinical testing for the treatment of patients with refractory mesial temporal lobe epilepsy.
    Preclinical
    |
    GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2)